Overexpression of EphA2, MMP‐9, and MVD‐CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis

Yang, Pu; Yuan, Weijie; He, Jie; Wang, Jiwei; Yu, Li; Jin, Xin; Hu, Yu; Liao, Mingmei; Chen, Zihua; Yang-de, Zhang

doi:10.1111/j.1872-034x.2009.00563.x

Cited by 61 publications

(46 citation statements)

References 25 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP9 is an important member of MMP family which is pivotal in degrading the basement membrane and has been proven to facilitate tumor invasion and metastasis in many types of cancer cells (19,28,29). It has also been shown that the invasive and metastatic capabilities of HCC were restrained by suppression of MMP9 (30,31). Indeed, in this study, we found that inhibition of MMP9 expression was associated with the suppression of HCC cell migration and invasion in vitro after overexpression of RIG-I.…”

Section: Discussionsupporting

confidence: 55%

RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9

Liu¹,

Dou²,

Jia³

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. The retinoic acid-induced protein I (Rig-I/Ddx58), (RIG-I) initiates a signaling cascade that induces innate immune defences which is associated with the production of type I interferons (IFNs) and inflammatory cytokines to establish an antiviral state. Aberrant RIG-I signaling leads to inflammation, autoimmune diseases and cancer. However, the role of RIG-I in hepatocellular carcinoma (HCC) is still unknown. Here, we observed that RIG-I expression was downregulated in HCC tissues and loss of RIG-I expression was correlated with poor clinicopathological features. Additionally, we demonstrated that patients with positive RIG-I expression had a better 3-year survival and RIG-I was an independent factor for predicting the prognosis of HCC patients. Elevated RIG-I expression inhibited the proliferation, migration, and invasion of HCC. Inhibiting RIG-I with its specific siRNA was able to attenuate the malignant behavior of HCC cells. Moreover, RIG-I inhibited the invasive behavior through downregulating matrix metalloproteinase-9 (MMP9). Mechanistically, RIG-I enhances IFN-α response by amplifying IFN-α effecter signaling via strengthening STAT1 activation. Addressing this pathway, we identified that RIG-I may serve as a prognostic marker and that MMP9 may be a potential target of RIG-I in HCC.

show abstract

Section: Discussionsupporting

confidence: 55%

RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9

Liu¹,

Dou²,

Jia³

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Sixteen Eph receptors, including EphA-1-A-10 and B-1-B-6, play an important role by specifically binding to the corresponding ligand in the growth and development of some diseases. 31 Studies have shown that EphA-2 is highly expressed in many cancers, including lung cancer, 32 hepatocellular carcinoma, 33 and breast cancer, 34 and have found that EphA-2 promoted tumor angiogenesis, cell proliferation, invasion and metastasis, and can predict the survival time and recurrence in patients with malignant tumors, also serving as a marker for studying the effects of new drugs. Here, we reported expression of EphA-2 in thyroid cancer for the first time.…”

Section: Discussionmentioning

confidence: 98%

Correlation of Clinicopathological Features and Expression of Molecular Markers With Prognosis After 131I Treatment of Differentiated Thyroid Carcinoma

Qin

Cau

Zhang

et al. 2012

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…33,34 CD-34 immunolabeling has also been recently associated with invasion and metastasis. 35 However, in contradiction with the previously mentioned studies, in a small series published by Zeng et al 36 including 70 consecutive patients treated with resection or transplantation, the authors reported that lower microvascular count confers a higher risk of recurrence after resection. Such inconsistency highlights the importance of adequate statistical power as a prerequisite to any study attempting to qualify or validate new prognostic markers in HCC.…”

Section: Microvessel Densitymentioning

confidence: 88%

Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Pinato

Pirisi

Maslen

et al. 2014

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Despite major advancements in the clinical management of hepatocellular carcinoma (HCC), the natural history of this disease is characterized by an invariably poor prognosis. However, there are significant interindividual variations in the biologic behavior of this tumor and this combined with the confounding effect of liver function on patient survival makes prognostic prediction particularly difficult. Several studies have attempted to investigate the prognostic role of tissue biomarkers to better understand the molecular basis of HCC progression. These studies have looked at several aspects of cancer biology including proliferative potential, invasive capacity, and angiogenic promotion utilizing different methodologies. The aim of this review is to summarize the role of tissue biomarkers in the prognostic prediction of HCC and to outline questions and strategies in the prognostic assessment of HCC.

show abstract

Overexpression of EphA2, MMP‐9, and MVD‐CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis

Abstract: Overexpressions of EphA2 and MMP-9 relate to tumor progression, metastasis, and prognosis in HCC. The present study suggests that EphA2 is associated with key mediators of angiogenesis and invasion.

Cited by 61 publications

References 25 publications

RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9

RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9

Correlation of Clinicopathological Features and Expression of Molecular Markers With Prognosis After 131I Treatment of Differentiated Thyroid Carcinoma

Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Contact Info

Product

Resources

About